Journal article

Targeting malignant glioma survival signalling to improve clinical outcomes

Michael LH Wong, Andrew H Kaye, Christopher M Hovens

JOURNAL OF CLINICAL NEUROSCIENCE | ELSEVIER SCI LTD | Published : 2007

Abstract

Malignant gliomas are common and aggressive brain tumours in adults. Current treatments for glioblastoma multiforme result in a poor median survival of less than 12 months. The blood-brain barrier restricts the delivery of many chemotherapies to the central nervous system, contributing to the failure of treatment. PI3K/Akt and Ras/MAPK pathways have been identified as important oncogenic pathways in these tumours. The PI3K/Akt pathway mediates cell survival and growth, whereas the Ras/MAPK pathway signals cell differentiation, proliferation and anti-apoptosis. Modern targeted therapies include antibodies to circulating growth factors and cell surface receptors, as well as inhibitors of recep..

View full abstract